SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 10,061.60 |
| Enterprise Value ($M) | 11,008.46 |
| Book Value ($M) | 3,529.99 |
| Book Value / Share | 15.88 |
| Price / Book | 2.85 |
| NCAV ($M) | -286.13 |
| NCAV / Share | -1.29 |
| Price / NCAV | -35.16 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.02 |
| Return on Assets (ROA) | 0.02 |
| Return on Equity (ROE) | 0.02 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.89 |
| Current Ratio | 2.17 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 2,454.07 |
| Assets | 6,270.20 |
| Liabilities | 2,740.20 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Wellington Management Group Llp | 9.49 | 404.21 | |
| 13G | BlackRock, Inc. | 10.20 | 2.53 | |
| 13G/A | Massachusetts Financial Services Co /ma/ | 10.50 | -0.26 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 99,461 | 882,232 | 11.27 | |
| 104,183 | 981,475 | 10.61 | |
| 76,642 | 536,731 | 14.28 | |
| 119,770 | 1,209,901 | 9.90 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PBH – Prestige Consumer Healthcare Inc. | PFE – Pfizer Inc. |
| PRGO – Perrigo Company plc | RCUS – Arcus Biosciences, Inc. |
| RFL – Rafael Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io